Emyria Managing Director, Dr Michael Winlo, recently presented on Broker Briefing – a digital platform for brokers and investors, featuring a range of ASX listed companies.

His presentation explores Emyria’s strategic commitment to novel drug development and registration, backed by world-class data systems and evidence-generation.

Watch Dr Winlo’s 20-minute presentation here: